Joint pain with high prevalence and yet without any specific treatment option is posing a challenge to healthcare professionals day by day. Amongst several treatment options currently utilized for arthritic joint pain are merely giving symptomatic relief rather than curative treatment. Non-steroidal Anti-inflammatory Drugs (NSAIDs) are the most widely accessed treatment option amongst all. But their adverse effects profile is a major hurdle for their use, especially in elderly patients. Present study was focused to develop a transdermal patch of a novel NSAID Loxoprofen sodium with enhanced penetration and improved patient compliance. Pluronic lecithin organogel (PLO) was selected as transdermal drug delivery platform to enhance its penetration through skin. Moreover transdermal route will bypass first pass metabolism, GI side effects and necessity to administer drug through oral route. All of these credentials ultimately improved patient compliance. Several experimental batches (PL1 to PL8) were formulated to prepare PLO of loxoprofen sodium. All the batches were evaluated for physical appearance, pH, viscosity, spreadability, drug content and in vitro drug diffusion profiles. An optimized batch was selected on the basis of obtained results. It showed sustained drug release upto 12 hrs. The study evidenced that similar transdermal formulations of other NSAIDs can significantly enhance current treatment scenario for joint pain. Moreover, conversion of such formulations in transdermal patch or other forms ensure sustained and reproducible transdermal flux which can be further fabricated as bioequivalent to the oral formulations. Further studies can be designed to evaluate the clinical applicability of the formulation.